Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats

Peng,Tao; Chang,Xiangdi; Wang,Jie; Zhen,Junhui; Yang,Xiangdong; Hu,Zhao

doi:10.3892/mmr.2017.6354

Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats

Authors:
- Tao Peng
- Xiangdi Chang
- Jie Wang
- Junhui Zhen
- Xiangdong Yang
- Zhao Hu
View Affiliations

Affiliations: Department of Nephrology, Shandong University Qilu Hospital, Jinan, Shandong 250012, P.R. China, Department of Nephrology, Affiliated Hospital of Binzhou Medical School, Yantai, Shandong 264003, P.R. China, Department of Nephrology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Pathology, Shandong University Qilu Hospital, Jinan, Shandong 250012, P.R. China
Published online on: March 22, 2017 https://doi.org/10.3892/mmr.2017.6354
Pages: 3172-3178

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the protective effect of tacrolimus on early podocyte damage in rats with diabetic nephropathy (DN). A total of 38 normal male Sprague‑Dawley rats were randomly divided into four groups: Normal control group (group N; n=8), DN group (n=10), tacrolimus (FK506) treatment group (group F; n=10), benazepril (Lotensin) treatment group (group L; n=10). The rats in groups DN, F and L were administered with streptozotocin (STZ; 60 mg/kg) by intraperitoneal injection to establish the diabetic rat model. After 4 weeks, the diabetic rat model was established, and rats in the different groups were administered intragrastically with the respective drugs. Blood glucose (BS), body weight (BW) and 24‑h urine protein were detected every 4 weeks, serum creatinine (SCr), blood urea nitrogen (BUN) and kidney weight/body weight (KW/BW) were measured at the end of the 8 weeks of drug treatment. Renal pathological changes were observed under a light microscope and electron microscope. Expression of nephrin, which is a podocyte‑specific marker, was detected using western blot analysis. The results showed that the levels of SCr, BUN, KW/BW and 24‑h urine protein in groups D, F and L were significantly higher, compared with those in group N (P<0.05). No significant differences were found between groups F and L for the above indicators, with the exception of BS. However, all indices were significantly lower, compared with those in group DN (P<0.05). Renal pathological expression was normal in group N under light microscopy. There were significant increases in the glomerular volume, proliferative mesangial cells, width of the mesangial area and thickness of the basement membrane in group DN, however, all the above pathological characteristics were reduced in groups F and L, compared with group DN (P<0.05). No significant difference was found between groups F and L. A widened glomerular basement membrane, and disorder, widening and fusion of podocyte processes were observed under the electron microscope in group DN, however, these were reduced in groups F and L, compared with group DN (P<0.05). The results of the western blot analysis showed that the expression of nephrin decreased by 60.1% in group DN, compared with group N, and significant recovery in the expression of nephrin was observed in groups F and L (P<0.05). Tacrolimus reduced urinary protein and slowed the progression of DN, partially by recovering the protein expression of nephrin in the renal tissue of diabetic rats, and maintaining the integrity of the structure and function of podocytes.

View Figures

View References

1	Usluogullari CA, Balkan F, Caner S, Ucler R, Kaya C, Ersoy R and Cakir B: The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocr Disord. 15:332015. View Article : Google Scholar : PubMed/NCBI
2	Ghaderian SB, Hayati F, Shayanpour S and Mousavi Beladi SS: Diabetes and end-stage renal disease; a review article on new concepts. J Renal Inj Prev. 4:28–33. 2015.PubMed/NCBI
3	Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC and Strippoli GF: Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis. Lancet. 385:2047–2056. 2015. View Article : Google Scholar : PubMed/NCBI
4	Tanaka N, Babazono T, Takagi M, Yoshida N, Toya K, Nyumura I, Hanai K and Uchigata Y: Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients. Nephrology (Carlton). 20:531–538. 2015. View Article : Google Scholar : PubMed/NCBI
5	Avogaro A and Fadini GP: The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care. 37:2884–2894. 2014. View Article : Google Scholar : PubMed/NCBI
6	Al-Mendalawi MD: Occurrence of microalbuminuria among children and adolescents with insulin-dependent diabetes mellitus. Saudi J Kidney Dis Transpl. 26:373–374. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Nie M, Lu Y, Wang R, Li J, Yang B, Xia M, Zhang H and Li X: Fucoidan exerts protective effects against diabetic nephropathy related to spontaneous diabetes through the NF-κB signaling pathway in vivo and in vitro. Int J Mol Med. 35:1067–1073. 2015.PubMed/NCBI
8	Aggarwal J and Kumar M: Prevalence of microalbuminuria among rural north indian population with diabetes mellitus and its correlation with glycosylated haemoglobin and smoking. J Clin Diagn Res. 8:CC11–CC13. 2014.PubMed/NCBI
9	Peng T, Hu Z, Wu L, Li D and Yang X: Correlation between endothelial dysfunction and left ventricular remodeling in patients with chronic kidney disease. Kidney Blood Press Res. 39:420–426. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yang X, Wang X, Nie F, Liu T, Yu X, Wang H, Li Q, Peng R, Mao Z, Zhou Q and Li G: miR-135 family members mediate podocyte injury through the activation of Wnt/β-catenin signaling. Int J Mol Med. 36:669–677. 2015.PubMed/NCBI
11	Wu Y, Dong J, Yuan L, Liang C, Ren K, Zhang W, Fang F and Shen J: Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine. 44:85–91. 2008. View Article : Google Scholar : PubMed/NCBI
12	Qi XM, Wu YG, Liang C, Zhang P, Dong J, Ren KJ, Zhang W, Fang F and Shen JJ: FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin. Int Immunopharmacol. 11:1613–1619. 2011. View Article : Google Scholar : PubMed/NCBI
13	Álamo JM, Olivares C, Barrera L, Marín LM, Suarez G, Bernal C, Serrano J, Muntané J, Padillo FJ and Gómez MA: Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant. World J Transplant. 5:19–25. 2015.PubMed/NCBI
14	Brouwers O, Niessen PM, Miyata T, Østergaard JA, Flyvbjerg A, Peutz-Kootstra CJ, Sieber J, Mundel PH, Brownlee M, Janssen BJ, et al: Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia. 57:224–225. 2014. View Article : Google Scholar : PubMed/NCBI
15	Liu XJ, Zhang YM, Wang SX and Liu G: Ultrastructural changes of podocyte foot processes during the remission phase of minimal change disease of human kidney. Nephrology (Carlton). 19:392–397. 2014. View Article : Google Scholar : PubMed/NCBI
16	Bohman SO, Jaremko G, Bohlin AB and Berg U: Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome. Kidney Int. 25:696–700. 1984. View Article : Google Scholar : PubMed/NCBI
17	Wu HS and Dikman S: Segmentation and thickness measurement of glomerular basement membranes from electron microscopy images. J Electron Microsc (Tokyo). 59:409–418. 2010. View Article : Google Scholar : PubMed/NCBI
18	Maestroni S, Maestroni A, Dell'Antonio G, Gabellini D, Terzi S, Spinello A, Meregalli G, Castoldi G and Zerbini G: Viable podocyturia in healthy individuals: Implications for podocytopathies. Am J Kidney Dis. 64:1003–1005. 2014. View Article : Google Scholar : PubMed/NCBI
19	Lin CL, Wang FS, Hsu YC, Chen CN, Tseng MJ, Saleem MA, Chang PJ and Wang JY: Modulation of Notch-1 signaling alleviates VEGF-mediated diabetic nephropathy. Diabetes. 59:1915–1925. 2010. View Article : Google Scholar : PubMed/NCBI
20	Tryggvason K: Unraveling the mechanisms of glomerular ultrafiltration: Nephrin, a key component of the slit diaphragm. J Am Soc Nephrol. 10:2440–2445. 1999.PubMed/NCBI
21	Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC and Bruijn JA: Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol. 14:2063–2071. 2003. View Article : Google Scholar : PubMed/NCBI
22	Langham RG, Kelly DJ, Cox AJ, Gow RM, Holthofer H and Gilbert RE: Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant. 19:262–263. 2004. View Article : Google Scholar : PubMed/NCBI
23	Toyoda M, Suzuki D, Umezono T, Uehara G, Maruyama M, Honma M, Sakai T and Sakai H: Expression of human nephrin mRNA in diabetic nephropathy. Nephrol Dial Transplant. 19:380–385. 2004. View Article : Google Scholar : PubMed/NCBI
24	Wallemacq PE and Reding R: FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: Clinical, biomedical, and analytical aspects. Clin Chem. 39:2219–2228. 1993.PubMed/NCBI
25	Liu LS, Li J, Chen XT, Zhang HX, Fu Q, Wang HY, Xiong YY, Liu S, Liu XM, Li JL, et al: Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: A 2-year prospective study. Int J Clin Pract Suppl. 43–52. 2015. View Article : Google Scholar : PubMed/NCBI
26	Bechstein WO, Paczek L, Wramner L, Squifflet JP and Zygmunt AJ: European Rapamune Tacrolimus Study Group: A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. Transplant Proc. 45:2133–2140. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC and Chan TM: Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology (Oxford). 53:2232–2237. 2014. View Article : Google Scholar : PubMed/NCBI
28	Bloch J, Hazzan M, Van der Hauwaert C, Buob D, Savary G, Hertig A, Gnemmi V, Frimat M, Perrais M, Copin MC, et al: Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. Pharmacogenomics. 15:2011–2024. 2014. View Article : Google Scholar : PubMed/NCBI
29	Jiang S, Tang Q, Rong R, Tang L, Xu M, Lu J, Jia Y, Ooi Y, Hou J, Guo J, et al: Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur J Pharmacol. 688:56–61. 2012. View Article : Google Scholar : PubMed/NCBI
30	Gooch JL, Barnes JL, Garcia S and Abboud HE: Calcineurin is activated in diabetes and is required for glomerul hypertrophy and ECM accumulation. Am J Physiol Renal Physiol. 284:F144–F154. 2003. View Article : Google Scholar : PubMed/NCBI
31	Qi XM, Wu YG, Liang C, Zhang P, Dong J, Ren KJ, Zhang W, Fang F and Shen JJ: FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin. Int Immunopharmacol. 11:1613–1691. 2011. View Article : Google Scholar : PubMed/NCBI
32	Peng T, Hu Z, Xia Q, Jiang B, Li X and Yang X: A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria. Arzneimittelforschung. 59:647–650. 2009.PubMed/NCBI
33	Jin H, Piao SG, Jin JZ, Jin YS, Cui ZH, Jin HF, Zheng HL, Li JJ, Jiang YJ, Yang CW and Li C: Synergistic effects of leflunomide and benazepril in streptozotocin-induced diabetic nephropathy. Nephron Exp Nephrol. 126:148–156. 2014. View Article : Google Scholar : PubMed/NCBI